State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, department of endocrinology, The first Affiliated Hospital of Xinjiang Medical University, No. 137 of Liyushannan Street, Xinshi District, Urumqi, 830054, China.
J Orthop Surg Res. 2024 Apr 20;19(1):250. doi: 10.1186/s13018-024-04717-9.
In this study, we investigated the relationship between sarcopenia and fatty liver in middle-aged and elderly patients diagnosed with type 2 diabetes mellitus (T2DM) to provide a theoretical foundation for the prevention and treatment of sarcopenia.
A total of 282 patients diagnosed with T2DM aged 50 and older and were admitted to the Endocrinology Department of Xin Medical University First Affiliated Hospital between December 2021 and February 2023, were selected. Body mass index (BMI), and limb and trunk muscle mass of the patients were measured, and data were collected. Patients were grouped based on the sarcopenia diagnostic criteria. All study participants underwent the same physical examinations and laboratory tests. The relationship between the onset of sarcopenia and fatty liver in middle-aged and elderly patients diagnosed with T2DM was then investigated using statistical analysis.
Comparing the sarcopenia group to the non-sarcopenia group revealed statistically significant variations in gender, BMI, fatty liver prevalence rate, uric acid (UA), alanine aminotransferase (ALT), blood glucose, blood lipid associated indicators, and limb skeletal muscle content. There were, however, no statistically significant differences in age, disease duration, hypertension, smoking, or alcohol intake. There was a positive correlation between BMI, UA, fasting c-peptide, and Appendicular Skeletal Muscle Index (ASMI). Higher levels of BMI, ASMI, and UA were identified as protective variables against sarcopenia by multifactorial logistic regression analysis.
Higher levels of BMI, ASMI, and UA can greatly reduce skeletal muscle atrophy in patients with T2DM. Patients with a fatty liver may be less vulnerable to sarcopenia. There is little evidence, however, that a fatty liver works as a preventive factor against sarcopenia.
本研究旨在探讨中老年 2 型糖尿病（T2DM）患者肌少症与脂肪肝的关系，为肌少症的防治提供理论依据。
选取 2021 年 12 月至 2023 年 2 月在新疆医科大学第一附属医院内分泌科就诊的年龄在 50 岁及以上、诊断为 T2DM 的患者 282 例，测量患者的体质量指数（BMI）、四肢及躯干肌肉量，收集资料，根据肌少症诊断标准对患者进行分组，所有研究对象均行相同的体格检查和实验室检查，采用统计学分析方法探讨中老年 T2DM 患者肌少症的发生与脂肪肝的关系。
与非肌少症组相比，肌少症组在性别、BMI、脂肪肝患病率、尿酸（UA）、丙氨酸氨基转移酶（ALT）、血糖、血脂相关指标及四肢骨骼肌含量方面存在统计学差异，在年龄、病程、高血压、吸烟、饮酒方面无统计学差异。BMI、UA、空腹 C 肽与四肢骨骼肌指数（ASMI）呈正相关。多因素 logistic 回归分析显示，较高的 BMI、ASMI 和 UA 是肌少症的保护因素。
较高的 BMI、ASMI 和 UA 可明显减少 T2DM 患者的骨骼肌萎缩，脂肪肝患者发生肌少症的风险可能较低，但脂肪肝作为肌少症的预防因素证据不足。
